Poxel S.A. (POXEL.PA)
EUR 0.13
(-0.94%)
EUR 0.13
(-0.94%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -28.76 Million EUR | -31.4% |
| 2022 | -21.89 Million EUR | 2.55% |
| 2021 | -22.46 Million EUR | 24.74% |
| 2020 | -29.84 Million EUR | -20.98% |
| 2019 | -24.67 Million EUR | -296.77% |
| 2018 | 12.53 Million EUR | 157.25% |
| 2017 | -21.9 Million EUR | 9.8% |
| 2016 | -24.28 Million EUR | -107.17% |
| 2015 | -11.72 Million EUR | -69.97% |
| 2014 | -6.89 Million EUR | 5.18% |
| 2013 | -7.27 Million EUR | -2.15% |
| 2012 | -7.11 Million EUR | 17.99% |
| 2011 | -8.68 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 FY | 1.98 Million EUR | 109.05% |
| 2023 Q4 | 1.02 Million EUR | 0.0% |
| 2023 Q2 | -348 Thousand EUR | 0.0% |
| 2022 FY | -21.89 Million EUR | 2.55% |
| 2022 Q4 | -10.26 Million EUR | 0.0% |
| 2022 Q2 | -935 Thousand EUR | 0.0% |
| 2021 FY | -22.46 Million EUR | 24.74% |
| 2021 Q2 | -8.42 Million EUR | 0.0% |
| 2021 Q4 | -16.42 Million EUR | 0.0% |
| 2020 Q2 | -13.69 Million EUR | 0.0% |
| 2020 FY | -29.84 Million EUR | -20.98% |
| 2020 Q4 | -18.67 Million EUR | 0.0% |
| 2019 FY | -24.67 Million EUR | -296.77% |
| 2019 Q1 | -6.39 Million EUR | -4.88% |
| 2019 Q2 | -7.44 Million EUR | -16.44% |
| 2019 Q4 | -21.6 Million EUR | 0.0% |
| 2018 FY | 12.53 Million EUR | 157.25% |
| 2018 Q4 | -6.09 Million EUR | 0.0% |
| 2018 Q1 | 3.4 Million EUR | 127.43% |
| 2018 Q2 | 6.4 Million EUR | 88.41% |
| 2017 Q2 | -9.5 Million EUR | -70.91% |
| 2017 FY | -21.9 Million EUR | 9.8% |
| 2017 Q4 | -12.39 Million EUR | 0.0% |
| 2017 Q1 | -5.56 Million EUR | 49.39% |
| 2016 Q1 | -6 Million EUR | 4.74% |
| 2016 Q4 | -10.99 Million EUR | 0.0% |
| 2016 FY | -24.28 Million EUR | -107.17% |
| 2016 Q2 | -12.19 Million EUR | -103.14% |
| 2015 Q2 | -5.03 Million EUR | -76.95% |
| 2015 FY | -11.72 Million EUR | -69.97% |
| 2015 Q4 | -6.29 Million EUR | -121.35% |
| 2015 Q3 | -2.84 Million EUR | 43.49% |
| 2015 Q1 | -2.84 Million EUR | 9.33% |
| 2014 Q4 | -3.13 Million EUR | 8.43% |
| 2014 Q3 | -3.42 Million EUR | 8.77% |
| 2014 Q2 | -3.75 Million EUR | -9.61% |
| 2014 Q1 | -3.42 Million EUR | 24.81% |
| 2014 FY | -6.89 Million EUR | 5.18% |
| 2013 FY | -7.27 Million EUR | -2.15% |
| 2013 Q4 | -4.55 Million EUR | 10.84% |
| 2013 Q2 | -2.71 Million EUR | 46.92% |
| 2013 Q3 | -5.11 Million EUR | -88.4% |
| 2013 Q1 | -5.11 Million EUR | 0.0% |
| 2012 Q3 | -1.78 Million EUR | 0.0% |
| 2012 FY | -7.11 Million EUR | 17.99% |
| 2012 Q1 | -1.78 Million EUR | 0.0% |
| 2012 Q2 | -1.78 Million EUR | 0.0% |
| 2012 Q4 | -5.11 Million EUR | -186.52% |
| 2011 Q2 | -2.15 Million EUR | 0.0% |
| 2011 FY | -8.68 Million EUR | 0.0% |
| 2011 Q1 | -2.15 Million EUR | 0.0% |
| 2011 Q4 | -1.78 Million EUR | 17.23% |
| 2011 Q3 | -2.15 Million EUR | 0.0% |
| 2010 Q4 | -2.15 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -743.025% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 77.418% |
| Adocia SA | -17.62 Million EUR | -63.228% |
| Aelis Farma SA | -6.46 Million EUR | -345.194% |
| Biophytis S.A. | -14.33 Million EUR | -100.684% |
| Advicenne S.A. | -6.45 Million EUR | -345.47% |
| genOway Société anonyme | 2.06 Million EUR | 1492.73% |
| IntegraGen SA | -183.77 Thousand EUR | -15552.174% |
| Medesis Pharma S.A. | -4.22 Million EUR | -580.106% |
| Neovacs S.A. | -6.9 Million EUR | -316.414% |
| NFL Biosciences SA | -4.43 Million EUR | -549.239% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -3596.046% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -816.853% |
| Sensorion SA | -22.31 Million EUR | -28.925% |
| Theranexus Société Anonyme | -7.64 Million EUR | -276.311% |
| TME Pharma N.V. | -5.62 Million EUR | -411.451% |
| Valbiotis SA | -7.16 Million EUR | -301.732% |
| TheraVet SA | -2.17 Million EUR | -1222.416% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -41.778% |
| argenx SE | -417.15 Million EUR | 93.105% |
| BioSenic S.A. | -7.04 Million EUR | -308.58% |
| Celyad Oncology SA | -8.45 Million EUR | -240.121% |
| DBV Technologies S.A. | -85.24 Million EUR | 66.258% |
| Galapagos NV | -88.26 Million EUR | 67.411% |
| Genfit S.A. | -26.58 Million EUR | -8.217% |
| GeNeuro SA | -14.35 Million EUR | -100.344% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -79.854% |
| Innate Pharma S.A. | -12.66 Million EUR | -127.042% |
| Inventiva S.A. | -102.7 Million EUR | 71.995% |
| MaaT Pharma SA | -19.94 Million EUR | -44.231% |
| MedinCell S.A. | -20.97 Million EUR | -37.122% |
| Nanobiotix S.A. | -26.77 Million EUR | -7.413% |
| Onward Medical N.V. | -35.46 Million EUR | 18.89% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -532.288% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -25.137% |
| Oxurion NV | -12.11 Million EUR | -137.523% |
| Pharming Group N.V. | -4.87 Million EUR | -489.481% |
| GenSight Biologics S.A. | -29.69 Million EUR | 3.138% |
| Transgene SA | -30.01 Million EUR | 4.158% |
| Financière de Tubize SA | -2.14 Million EUR | -1241.621% |
| UCB SA | 604 Million EUR | 104.762% |
| Valneva SE | -82.08 Million EUR | 64.959% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 0.253% |